Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists.

Comfort S, Dorrell D, Meireis S, Fine J.

Drug Saf. 2018 Nov;41(11):1073-1085. doi: 10.1007/s40264-018-0690-y.

2.

Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.

Théophile H, Arimone Y, Miremont-Salamé G, Moore N, Fourrier-Réglat A, Haramburu F, Bégaud B.

Drug Saf. 2010 Nov 1;33(11):1045-54. doi: 10.2165/11537780-000000000-00000.

PMID:
20925441
3.
4.

Comparison of different methods for causality assessment of adverse drug reactions.

Behera SK, Das S, Xavier AS, Velupula S, Sandhiya S.

Int J Clin Pharm. 2018 Aug;40(4):903-910. doi: 10.1007/s11096-018-0694-9. Epub 2018 Jul 26.

PMID:
30051231
5.

Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.

Comfort S, Perera S, Hudson Z, Dorrell D, Meireis S, Nagarajan M, Ramakrishnan C, Fine J.

Drug Saf. 2018 Jun;41(6):579-590. doi: 10.1007/s40264-018-0641-7.

6.
7.

Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying Deep-learning Approaches to Individual Case Safety Report Processing.

Abatemarco D, Perera S, Bao SH, Desai S, Assuncao B, Tetarenko N, Danysz K, Mockute R, Widdowson M, Fornarotto N, Beauchamp S, Cicirello S, Mingle E.

Pharmaceut Med. 2018;32(6):391-401. doi: 10.1007/s40290-018-0251-9. Epub 2018 Oct 13.

8.

Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.

Das S, Behera SK, Xavier AS, Velupula S, Dkhar SA, Selvarajan S.

Clin Drug Investig. 2018 Mar;38(3):211-218. doi: 10.1007/s40261-017-0601-5.

PMID:
29185238
9.

An assessment of reported adverse drug reactions in a Tertiary Care Hospital in South India: A retrospective cross-sectional study.

Gupta SK, Kumar KD.

Int J Pharm Investig. 2017 Oct-Dec;7(4):193-197. doi: 10.4103/jphi.JPHI_81_17.

10.

Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.

Théophile H, Dutertre JP, Gérardin M, Valnet-Rabier MB, Bidault I, Guy C, Haramburu F, Hillaire-Buys D, Méglio C, Arimone Y.

Therapie. 2015 Sep-Oct;70(5):465-76. doi: 10.2515/therapie/2015028. Epub 2015 Jun 26.

PMID:
26423144
11.

Agreement of expert judgment in causality assessment of adverse drug reactions.

Arimone Y, Bégaud B, Miremont-Salamé G, Fourrier-Réglat A, Moore N, Molimard M, Haramburu F.

Eur J Clin Pharmacol. 2005 May;61(3):169-73. Epub 2005 Apr 13.

PMID:
15827761
12.

Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.

Tozzi AE, Asturias EJ, Balakrishnan MR, Halsey NA, Law B, Zuber PL.

Vaccine. 2013 Oct 17;31(44):5041-6. doi: 10.1016/j.vaccine.2013.08.087. Epub 2013 Sep 8.

PMID:
24021304
13.

Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs.

Kane-Gill SL, Forsberg EA, Verrico MM, Handler SM.

Drug Saf. 2012 Aug 1;35(8):645-53. doi: 10.2165/11599730-000000000-00000.

PMID:
22720659
14.

Accuracy and reproducibility of two scales in causality assessment of unexpected hepatotoxicity.

Miljkovic MM, Dobric S, Dragojevic-Simic V.

J Clin Pharm Ther. 2012 Apr;37(2):196-203. doi: 10.1111/j.1365-2710.2011.01282.x. Epub 2011 Jul 1.

PMID:
21718339
15.

Key elements in adverse drug interaction safety signals: an assessment of individual case safety reports.

Strandell J, Norén GN, Hägg S.

Drug Saf. 2013 Jan;36(1):63-70. doi: 10.1007/s40264-012-0003-9.

PMID:
23315297
16.

Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.

Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N.

Drug Saf. 2017 Apr;40(4):317-331. doi: 10.1007/s40264-016-0491-0.

17.

A supervised adverse drug reaction signalling framework imitating Bradford Hill's causality considerations.

Reps JM, Garibaldi JM, Aickelin U, Gibson JE, Hubbard RB.

J Biomed Inform. 2015 Aug;56:356-68. doi: 10.1016/j.jbi.2015.06.011. Epub 2015 Jun 24.

18.

Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity.

Miljkovic MM, Dobric S, Dragojevic-Simic V.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):272-85. doi: 10.1002/pds.2081. Epub 2011 Jan 10.

PMID:
21351309
19.

Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.

García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ; Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham).

Aliment Pharmacol Ther. 2008 May;27(9):780-9. doi: 10.1111/j.1365-2036.2008.03655.x. Epub 2008 Feb 18.

20.

Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.

Trippe ZA, Brendani B, Meier C, Lewis D.

Drug Saf. 2017 Apr;40(4):293-303. doi: 10.1007/s40264-016-0499-5.

PMID:
28130773

Supplemental Content

Support Center